Exelixis (EXEL) Net Cash Flow (2010 - 2026)
Exelixis' (EXEL) quarterly Net Cash Flow came in at -$256.3 million in Q2 2026, down 662.41% year-on-year from $45.6 million in Q2 2025, and down 341.4% quarter-over-quarter from $106.2 million in Q1 2026.
Exelixis (EXEL) Net Cash Flow (2010 - 2026) Analysis & Trends
Exelixis' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$256.3 million for Q2 2026.
- On a quarterly basis, Net Cash Flow fell 662.41% year-over-year to -$256.3 million in Q2 2026; TTM through Apr 2026 was $42.4 million, a 155.93% increase from a year earlier, with the FY2026 full-year figure at $265.1 million, up 681.14% from the prior year.
- Net Cash Flow eased to -$256.3 million in Q2 2026 per EXEL's latest filing, from $106.2 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $211.9 million in Q4 2025 and bottomed at -$256.3 million in Q2 2026.
- The 5-year median for Net Cash Flow is -$33.6 million (2025), against an average of -$25.7 million.
- Across the five-year window, Net Cash Flow sank 879.38% in 2025 and soared 359.17% in 2026, its largest moves.
- Year by year, Net Cash Flow stood at -$174.1 million in 2022, then increased by 23.11% to -$133.9 million in 2023, then surged by 144.74% to $59.9 million in 2024, then jumped by 253.78% to $211.9 million in 2025, then tumbled by 220.99% to -$256.3 million in 2026.
- Per Business Quant, the three latest EXEL Net Cash Flow figures stand at -$256.3 million (Q2 2026), $106.2 million (Q1 2026), and $211.9 million (Q4 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 10.56 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 224.46 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.34 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 457.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -152.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 57.19 Mn |
| 10 | Exelixis | 14.38 Bn | 13.60 Bn | 590.86 Mn | -256.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | -256.34 Mn |
| Apr 3, 2026 | -256.34 Mn |
| Jan 2, 2026 | 106.19 Mn |
| Jan 2, 2026 | 106.19 Mn |
| Oct 3, 2025 | 211.87 Mn |
| Oct 3, 2025 | 211.87 Mn |
| Jul 4, 2025 | -19.32 Mn |
| Jul 4, 2025 | -19.32 Mn |
| Apr 4, 2025 | -33.62 Mn |
| Apr 4, 2025 | -33.62 Mn |
| Jan 3, 2025 | -40.97 Mn |
| Jan 3, 2025 | -40.97 Mn |
| Sep 27, 2024 | 59.89 Mn |
| Sep 27, 2024 | 59.89 Mn |
| Jun 28, 2024 | -61.10 Mn |
| Jun 28, 2024 | -61.10 Mn |
| Mar 29, 2024 | -3.43 Mn |
| Mar 29, 2024 | -3.43 Mn |
| Dec 29, 2023 | -133.87 Mn |
| Dec 29, 2023 | -133.87 Mn |